Organisation paid for research Program year 2025 Source: CMS Open Payments

Keystone Operations LLC

Neither a doctor nor a teaching hospital

Research payments

$111,137

13 payments

Through program year 2025, Keystone Operations LLC is reported as receiving $111,137 in research payments, across 13 payments.

By program year

2 rows

Year	Kind	Amount	Payments
2025	Research	$45,215	3
2024	Research	$65,922	10

Breakdown

Who paid Research payments · program years 2024–2025

AbbVie, Inc. $100,637 11 payments
Ocular Therapeutix, Inc. $7,000 1 payment
Oyster Point Pharma, Inc. $3,500 1 payment

Studies the money was for Research payments · program years 2024–2025

Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension $22,272 1 payment
A Phase 3b Study to Evaluate the Duration of Effect of Bimatoprost SR in Participants with Open-Angle Glaucoma or Ocular Hypertension $18,522 1 payment
1698-302-007 Ph3 Extension Study (M21-489) $17,684 1 payment
Long-term Safety and Efficacy Extension Trial of Bimatoprost SR $12,612 1 payment
1698-301-007 Ph3b Study (M21-488) $11,032 1 payment
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration $7,000 1 payment
A Phase 1/2 Study to Evaluate the Safety and Efficacy of AGN-193408 SR in Participants With Open-Angle Glaucoma or Ocular Hypertension $5,750 1 payment
Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension $4,966 2 payments
An Extension Trial to Evaluate the Long-term Safety and Efficacy of Bimatoprost SR in Patients with Open Angle Glaucoma or Ocular Hypertension $4,421 1 payment
A Randomized, Double-Masked, Vehicle-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% Ophthalmic Ointment (MR-139), in Subjects With Blepharitis $3,500 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.